Is Eris Lifesciences a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Eris Lifesciences Ltd is a good quality company .

Is Eris Lifesciences undervalued or overvalued?

The key valuation ratios of Eris Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Eris Lifesciences share price return in the past 10 years?

Data is not available for this company

Is Eris Lifesciences a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Eris Lifesciences Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

Eris Lifesciences Ltd - Stock Valuation and Financial Performance

Name: Eris Lifesciences
Brand: Eris Lifesciences

BSE: 540596 | NSE: ERIS | Pharmaceuticals & Drugs | Small Cap

Place order

Eris Lifesciences Share Price

₹1,737.40 6.15 0.36%
as on 10-Jul'25 16:59

Eris Lifesciences Ltd - Stock Valuation and Financial Performance

BSE: 540596 | NSE: ERIS | Pharmaceuticals & Drugs | Small Cap

Place order

Eris Lifesciences Share Price

₹1,737.40 6.15 0.36%
as on 10-Jul'25 16:59

10 Year X-Ray of Eris Lifesciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	54.6%	62.6%	35.8%	26.5%	25.4%	27.6%	25.3%	17.3%	12.4%	13.6%	-
Value Creation Index ⓘ	3.9	3.5	1.7	1.0	0.9	1.0	0.9	0.3	-0.1	0.0	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	597	750	856	982	1,074	1,212	1,347	1,685	2,009	2,894	2,894
Sales YoY Gr.	-	25.5%	14.2%	14.8%	9.4%	12.8%	11.2%	25.1%	19.2%	44%	-
Adj EPS ⓘ	9.6	16.7	20.2	21	21.6	26	30	27.8	28.6	25.7	25.8
YoY Gr.	-	74.8%	20.5%	4.3%	2.7%	20.5%	15.3%	-7.1%	2.6%	-9.9%	-
BVPS (₹) ⓘ	21.7	41.3	62.6	83.6	95.3	115.8	140.3	161.3	189.8	208.8	208.8
Adj Net Profit ⓘ	132	230	277	289	293	353	408	379	388	350	352
Cash Flow from Ops. ⓘ	131	200	235	223	271	375	378	292	486	1,065	-
Debt/CF from Ops. ⓘ	0	0	1.6	0.8	0	0	0.1	2.9	5.6	2.3	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	19.2%	21.9%	29%	44%
Adj EPS ⓘ	11.6%	3.6%	-5%	-9.9%
BVPSⓘ	28.6%	17%	14.2%	10%
Share Price	-	31.2%	38.6%	67.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	46.5	53.1	38.8	28.7	24	24.6	23.4	18.5	16.2	12.9	12.4
Op. Profit Mgn % ⓘ	28.8	35.9	37.7	35.2	34.7	35.6	36.3	32	33.7	35.2	35.3
Net Profit Mgn % ⓘ	22.3	30.7	32.5	29.5	27.3	29.1	30.2	22	19.6	12.9	12.2
Debt to Equity ⓘ	0	0	0.4	0.2	0	0	0	0.4	1.1	0.9	0.6
Working Cap Days ⓘ	68	77	101	118	130	136	145	143	159	138	79
Cash Conv. Cycle ⓘ	12	11	-4	-4	7	14	13	29	37	34	-3

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 29.03%

Debt to equity has declined versus last 3 years average to 0.85

Sales growth is good in last 4 quarters at 45.23%

Return on Equity has declined versus last 3 years average to 12.40%

Net Profit has been subdued in last 3 years -4.97%

Latest Financials - Eris Lifesciences Ltd.

	Standalone	Consolidated
TTM EPS (₹)	5.7	25.8
TTM Sales (₹ Cr.)	1,698	2,894
BVPS (₹.) ⓘ	183.9	208.8
Reserves (₹ Cr.) ⓘ	2,491	2,831
P/BV ⓘ	9.45	8.32
PE ⓘ	305.76	67.25

From the Market
52 Week Low / High (₹)	988.95 / 1909.55
All Time Low / High (₹)	341.05 / 1909.55
Market Cap (₹ Cr.)	23,663
Equity (₹ Cr.)	13.6
Face Value (₹)	1
Industry PE ⓘ	41.5

Management X-Ray of Eris Lifesciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

11.37

10.95

18.51

* Pledged shares as % of Promoter's holding (%)

Valuation of Eris Lifesciences

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

ERIS Lifesciences: Q1FY24 Result Update

19 Aug, 2023

Key Ratios of Eris Lifesciences

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	597	749	856	982	1,074	1,212	1,347	1,685	2,009	2,894
Operating Expenses ⓘ	425	480	533	637	706	781	862	1,148	1,334	1,876
Manufacturing Costs	11	8	8	11	19	15	43	21	36	60
Material Costs	98	134	142	154	172	238	259	352	380	714
Employee Cost	125	131	157	191	206	229	250	346	404	505
Other Costs ⓘ	191	207	227	281	310	298	310	429	515	597
Operating Profit ⓘ	172	269	322	345	368	431	485	537	675	1,017
Operating Profit Margin (%)	28.8%	35.9%	37.6%	35.1%	34.3%	35.5%	36.0%	31.9%	33.6%	35.2%
Other Income ⓘ	3	25	26	32	16	9	26	11	24	18
Interest ⓘ	0	1	11	23	2	2	4	26	85	231
Depreciation ⓘ	20	23	26	36	50	43	65	117	183	315
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	154	270	312	317	331	394	442	405	431	489
Tax ⓘ	20	24	17	26	35	39	36	30	34	114
Profit After Tax	135	247	295	291	297	355	406	374	397	375
PAT Margin (%)	22.6%	32.9%	34.5%	29.6%	27.6%	29.3%	30.1%	22.2%	19.8%	12.9%
Adjusted EPS (₹)	9.7	18.0	21.4	21.2	21.8	26.2	29.9	28.1	28.8	25.8
Dividend Payout Ratio (%)	62%	0%	0%	0%	13%	21%	20%	26%	0%	28%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund	300	567	861	1,149	1,293	1,572	1,906	2,193	2,581	2,844
Share Capital ⓘ	0	14	14	14	14	14	14	14	14	14
Reserves ⓘ	299	553	848	1,136	1,280	1,559	1,893	2,180	2,568	2,831
Minority Interest	3	24	25	18	0	0	-0	25	636	417
Debt	0	0	274	0	0	0	45	699	1,966	2,134
Long Term Debt	0	0	274	0	0	0	45	644	655	1,738
Short Term Debt	0	0	0	0	0	0	0	55	1,311	397
Trade Payables	25	39	91	84	100	103	118	125	219	332
Others Liabilities ⓘ	64	102	177	229	43	28	44	430	1,409	1,134
Total Liabilities ⓘ	392	732	1,428	1,481	1,437	1,703	2,113	3,472	6,810	6,862
Fixed Assets
Gross Block	123	254	820	838	984	1,006	1,092	2,843	4,773	6,061
Accumulated Depreciation	52	23	48	78	109	152	174	275	454	754
Net Fixed Assetsⓘ	71	232	771	761	875	854	918	2,568	4,319	5,306
CWIP ⓘ	0	0	0	3	4	2	27	22	20	67
Investmentsⓘ	190	303	365	356	78	294	520	37	16	67
Inventories	48	56	65	83	69	94	118	131	189	335
Trade Receivables	25	49	67	84	157	140	161	293	422	459
Cash Equivalents	10	2	11	8	67	38	52	58	1,401	223
Others Assetsⓘ	48	90	149	187	186	280	316	363	444	405
Total Assets ⓘ	392	732	1,428	1,481	1,437	1,703	2,113	3,472	6,810	6,862

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ	131	200	235	223	271	375	378	292	486	1,065
PBT ⓘ	154	270	312	317	331	394	442	405	431	489
Adjustment ⓘ	20	-1	14	31	44	44	49	140	254	548
Changes in Working Capital ⓘ	-8	-16	-22	-53	-53	5	-30	-176	-99	126
Tax Paid ⓘ	-35	-53	-70	-72	-52	-69	-83	-77	-101	-98
Cash Flow From Investing Activity ⓘ	-44	-184	-590	-5	123	-323	-320	-982	-1,855	-80
Capex	-24	-50	-25	-37	-146	-26	-120	-841	-129	-155
Net Investments	-21	-135	-38	35	288	-295	-188	-165	-1,731	67
Others ⓘ	0	0	-527	-3	-19	-3	-11	24	5	8
Cash Flow From Financing Activityⓘ	-84	-24	363	-221	-335	-82	-45	688	1,380	-881
Net Proceeds from Shares ⓘ	0	0	0	1	0	0	7	2	5	7
Net Proceeds from Borrowing ⓘ	-1	-7	373	-200	-176	0	45	785	1,464	-397
Interest Paid ⓘ	0	0	-10	-22	-2	-2	-4	-23	-77	-145
Dividend Paid ⓘ	-83	-17	0	0	-47	-75	-82	-100	0	-100
Others ⓘ	0	0	0	0	-110	-6	-11	24	-11	-246
Net Cash Flow ⓘ	4	-8	8	-3	60	-30	14	-2	11	104

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	47.68	56.9	41.3	28.96	24.28	24.78	23.33	18.25	16.64	13.81
ROCE (%)	54.56	62.56	35.76	26.54	25.44	27.6	25.29	17.3	12.37	13.59
Asset Turnover Ratio	1.65	1.33	0.79	0.68	0.74	0.79	0.73	0.63	0.41	0.43
PAT to CFO Conversion(x)	0.97	0.81	0.8	0.77	0.91	1.06	0.93	0.78	1.22	2.84
Working Capital Days
Receivable Days	15	18	25	28	41	44	39	47	62	54
Inventory Days	31	25	26	28	26	24	28	26	28	32
Payable Days	114	86	167	208	196	155	156	126	165	141

Eris Lifesciences Ltd Stock News

Eris Lifesciences Ltd FAQs

What is the share price of Eris Lifesciences?

Company share prices are keep on changing according to the market conditions. The closing price of Eris Lifesciences on 10-Jul-2025 16:59 is ₹1,737.4.

What is the market cap of Eris Lifesciences?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Jul-2025 16:59 the market cap of Eris Lifesciences stood at ₹23,662.9.

What is the P/E ratio of Eris Lifesciences?

The latest P/E ratio of Eris Lifesciences as of 10-Jul-2025 16:59 is 305.8.

What is the P/B ratio of Eris Lifesciences?

The latest P/B ratio of Eris Lifesciences as of 10-Jul-2025 16:59 is 9.45.

What is the 52-week high and low of Eris Lifesciences?

The 52-week high of Eris Lifesciences is ₹1,909.6 and the 52-week low is ₹989.0.

What is the TTM revenue of Eris Lifesciences?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Eris Lifesciences is ₹1,698 ( Cr.) .

About Eris Lifesciences Ltd

Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. The company’s focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by superspecialist and specialist doctors. Eris features amongst the Top 30 companies in the Indian Branded Formulations Market.

The company’s core commitment is towards improving health care outcomes and adding value for all its stakeholders including patients, doctors, regulators, employees and business partners. The company is making ongoing efforts to innovate its products to bring the best clinical practices in health care industry to its customers.

The company’s product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists.

Business area of the company

The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.

History and milestones

2007: Incorporation of the company.
2007: Launched “Eris” division focused on cardiology and diabetes segment.
2008: Launched “Nikkos” division focused on gastroenterology and orthopedics segment.
2009: Launched “Adura” division focused on cardiology and diabetes segment.
2011: Launched “Montana” division focused on gynecology and pediatrics segment.
2012: Launched “Inspira” division focused on cardiology segment.
2014: Launched “Victus” division focused on anti-diabetes segment.
2014: Set up Assam Facility by the company.
2015: Launched “Eris 2” division focused on pain management segment.
2016: Acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited).
2016: Acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited.
2016: Acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited.
2017: Acquired the trademarks ‘UNION’, ‘REUNION’ and ‘BON UNION’.
2017: Eris acquires 40 trademarks from Amay Pharma
2017: Eris acquires Pune based UTH Healthcare.
2018: Eris entered into a distribution agreement with India Medtronic Private Limited.
2019: Eris Lifesciences acquires trademark Zomelis from Novartis AG for $13 mn.
2019: Eris partners with Pharmanutra S.P.A of Italy for Sideral.

SEBI Registered: Investment Adviser - INA000013323 RIA Details

Warning: Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer: Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provides any assurance of returns to investors.

Compliance Officer:

Name: Shrikant Jagtap

Email: shrikant.jagtap@moneyworks4me.com

Mobile No: +91 97638 00745

Grievance Officer:

Name: Mukta Vaze

Email: mukta.vaze@moneyworks4me.com

Mobile No:+91 98609 19463

Principal Officer:

Name: Atharva Bhide

Email: atharva.bhide@moneyworks4me.com

Mobile No:+91 91758 99463

SEBI regional/local office address-

Plot No. C 4-A , G Block, Near Bank of India, Bandra Kurla Complex, Bandra East, Mumbai, Maharashtra 400051

Address:

The Alchemists Ark Pvt. Ltd., B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Data provided by Accord Fintech Pvt. Ltd.

Please wait your portfolio is updating...

Particulars	Q1FY24	YoY Trend	Comments
Revenue	467	+17%	21% Branded formulations segment growth on 20% YPM* growth
EBITDA	170	+32%
EBITDA Margin	36%	+407 bps	Increased gross margin and operating leverage benefits resulted in margin expansion
PAT	94	+1%	Depreciation and interest cost adversely impacted PAT

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity - May 16, 2019 - Perpetual
BASL Membership ID:	BASL1187
Address	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Eris Lifesciences Ltd - Stock Valuation and Financial Performance

Eris Lifesciences Share Price

Eris Lifesciences Ltd - Stock Valuation and Financial Performance

Eris Lifesciences Share Price

DeciZen - make an informed investing decision on Eris Lifesciences Share

Overall Rating ⓘ

1. Quality

2. Valuation

3. Price Trend

Eris Lifesciences stock performance -

Is Eris Lifesciences Ltd an attractive stock to invest in?

1. Is Eris Lifesciences Ltd a good quality company?

2. Is Eris Lifesciences Ltd undervalued or overvalued?

3. Is Eris Lifesciences Ltd a good buy now?

10 Year X-Ray of Eris Lifesciences: Share

Analysis of Financial Track Record

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Recent Performance Summary

Latest Financials - Eris Lifesciences Ltd.

Management X-Ray of Eris Lifesciences: Share

Shareholding Pattern

Promoter's Holding & Share Pledging